Latest Breaking News On - Group or sirnaomics - Page 1 : comparemela.com

Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi.

United statesJim weteringsCompany galaheadPrnewswire sirnaomics ltdRna therapeutics congressRna therapeutics congress presentation detailsGroup or sirnaomicsCongress presentationTherapeutic platformVice presidentPlenary keynote sessionPlenary chairperson

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors

Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging .

Hong kongUnited statesPatrick luDavid evansSirnaomics ltdGroup or sirnaomicsCompany galaheadStock codeImmune checkpoint inhibitorExecutive directorChief executive officer

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavid evansPatrick luGroup or sirnaomicsPrnewswire sirnaomics ltdCompany galaheadStock codeImmune checkpoint inhibitorExecutive directorChief executive officer

RNAimmune Receives Investigational New Drug Application Clearance from U S FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770

GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today.

United statesDong shenPatrick luDewan zengPrnewswire sirnaomics ltdZhejiang innoforce pharmaceuticals co ltdRnaimmune incDrug administrationGroup or sirnaomicsInternational bioislandStock codeInvestigational new drugRespiratory syncytial virusChief executive officerPolypeptide lipid nanoparticle

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 5, 2023 /PRNewswire/ Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi.

United statesFrancois lebelSirnaomic galaheadPatrick luGroup or sirnaomicsGroup factor xi programPrnewswire sirnaomics ltdStock codeExecutive directorChief executive officerChief medical officer